For some, agreed, the new drugs can provide a port in an horrific storm. The lack of an MOA in BG 12 issue was brought up by David Cavalla, a pharmaceutical reporter. I copy and paste. The PML issue is just surfacing.
My concern is that some
neurologists, not all, do not disclose potential side effects of the newer drugs. Jeff was given the hard sale for tysabri by his neuro at his yearly appointment a couple years ago--even though he had no inflammation, no progression, no new lesions or disabilities and his gray matter looked normal on MRI. She said, "you are a man, you will
progress--trust me, you want to do all you can." He told her his concerns with the drug, said he was doing well. Thanks, but no thanks. And she relented. The most recent appointment, he's still well, she told him to keep doing what he's doing. I hear from patients all over the internet who have been given this same story. Take this, to prevent future damage. And to those who do not know all the facts--taking the "most effective" drug, even though they're doing OK, seems like preventative medicine. We all want "the best." Whether it's the most prestigious neuro, highly regarded MS center, or effective drug. But it's not that simple. What happens if they become JC positive? The washout period for Tysabri (and potentially BG 12) can cause more inflammation and progression. The subdued immune system roars back to life. http://ms.about.com/b/2011/02/09/the-ty ... effect.htm
I feel it's important for patients to be fully informed about all the options.
Especially now that Tysabri is applying for use as a first line medication.....this truly worries me. I share Harry's concern.
http://www.reuters.com/article/2013/01/ ... J720130116
Tysabri use is currently limited to between 10 and 12 percent of treated MS patients, due to the risk of PML, and analysts said the hoped-for wider approval would improve uptake and send a positive signal to doctors.
Berenberg analysts said Tysabri's share of the MS market could increase to about 15 percent by 2015, representing sales of $2.9 billion, while today's share price for Elan implied peak sales of only some $2 billion.